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Abstract. Objective: We investigated the effect of pre-treat-
ment with ondansetron or CP 93129 (a 5-HT1B agonist) on
the antinociceptive activity of paracetamol and the changes
in central 5-HT3 receptors induced by paracetamol alone or
co-administered with ondansetron.
Materials and Subjects: Male Wistar rats (eight per group)
were injected with ondansetron (2 and 4 mg/kg s.c.) or CP
93129 (0.5, 1 and 2 mg/kg s.c.) 15 min before paracetamol
(400 mg/kg, i.p.).
Methods: Pain threshold was evaluated in the hot-plate or in
the paw pressure test 30 min after the last treatment. 5-HT3
receptor binding capacity was measured in the frontal cortex,
temporal-parietal cortex and midbrain by means of radioli-
gand binding technique. Statistical analysis was done using
ANOVA followed by Student-Newman-Keuls test and 2 X 2
factorial analysis when appropriate.
Results: Pre-treatment with ondansetron, at doses of 2 and 
4 mg/kg, did not affect the antinociceptive activity of parac-
etamol in the hot-plate test and in the paw pressure test.
Paracetamol did not change the characteristics of 5-HT3
receptors in all the areas investigated. Ondansetron (4 mg/kg
s.c) per se significantly increased the 5-HT3 receptor number
in the areas used, the effect not being modified by co-admin-
istration with paracetamol. On the other hand, CP 93129 
(2 mg/kg s.c.) significantly prevented the effect of paraceta-
mol in both algesimetric tests used.
Conclusions: Our data indicate that 5-HT1B but not 5-HT3
receptors are involved in the antinociceptive effect of parac-
etamol in our experimental conditions.
Keywords: Paracetamol – Antinociception – 5-HT1B and 
5-HT3 receptors – Ondansetron – CP 93129 – Brain
Introduction
Many reports indicate that paracetamol exerts its antinoci-
ceptive activity acting not only peripherally, but also within
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the central nervous system (CNS) both at spinal and
supraspinal level [1–3]. It has been suggested that a number
of neurotransmitter systems may be involved in the central
analgesic activity of paracetamol; in particular serotonin 
(5-HT) pathways seem to play a pivotal role in the central
mechanism of action of this drug [4–6]. In our previous
works we have demonstrated the importance of the central
serotonergic system in the antinociceptive effect of paraceta-
mol which matches an increase in the serotonin levels and a
decrease in the number of 5-HT2 receptors in the cerebral
cortex of the rat [6].
Indeed, multiple serotonin subtypes have been identified
within the central nervous system and 5-HT1, 5-HT2 and 
5-HT3 receptors are now thought to be involved in the 5-HT-
mediated antinociceptive mechanism [7]. There are conflict-
ing findings concerning the relationship between the
antinociceptive effects of 5-HT to specific subtypes of 5-HT
receptors; recently it has been suggested that 5-HT2 and 
5-HT3 receptors mediate antinociception to chemical stimuli
in the spinal cord [8]. Some reports indicate that, at spinal
level, 5-HT3 receptors have an important role in the analgesic
effect of paracetamol [9]. 5-HT3 receptors are concentrated
in the dorsal horn of the spinal cord [10], but are present also
in some CNS areas, chiefly in the hippocampus, limbic and
cortical areas [11].
5-HT1B receptors have been recently proposed to be
involved in the antinociceptive action of some drugs. It has
been reported that 5-HT1B receptors are predominantly locat-
ed on nerve terminals [12] where they regulate neurotrans-
mitter release. Activation of 5-HT1B autoreceptors on sero-
tonergic terminals resulted in inhibition of serotonin release
from hippocampus and frontal cortex in rats [13]. It has also
been shown that 5-HT1B receptors work as heteroreceptors to
inhibit the release of other neurotransmitters (glutamate,
GABA and acetylcholine) [14]. 5-HT1B receptors are present
in the dorsal root ganglia, spinal cord and trigeminal nucleus
[15], but also in many CNS regions, including the frontal 
cortex [16].
Therefore, in the light of the findings that 5-HT3 recep-
tors might be involved in the mechanism of the antinocicep-
tive action of paracetamol at spinal level, and that they are
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present also in higher brain centres, we decided to evaluate
the role of these serotonergic receptors at supraspinal level as
well. This we did by studying the influence of the pre-treat-
ment with ondansetron, a specific antagonist of 5-HT3 recep-
tors, on the antinociceptive effect of paracetamol, evaluated
by means of the hot-plate and of the paw pressure tests.
Moreover, since it has been shown that 5-HT1B receptor
antagonists increased basal levels of serotonin while their
activation decreased serotonin levels [17], we decided to test
the influence of CP 93129, a 5HT1B receptor agonist, on the
antinociception exerted by paracetamol on the two above
mentioned tests.
To exclude the 5-HT3 receptors’ involvement in the
antinociceptive effect of paracetamol from a biochemical
point of view, we investigated the capability of paracetamol
to bind to or to modify the characteristics of 5-HT3 receptors
in three brain areas. Moreover, we studied the influence of
pre-treatment with ondansetron on the possible changes




Male Wistar rats weighing 180–200 g were housed in Plexiglas® cages
in groups of three in controlled conditions (free access to food and
water; 12-h dark/light cycle; temperature, 22 ± 1°C; humidity, 60%).
The ethical guidelines for investigation of experimental pain in con-
scious animals were followed, and procedures were carried out accord-
ing EEC ethical regulations for animal research (EEC Council 86/609;
D.L. 27/01/1982, No. 116).
Drug treatment
The rats were randomly divided into groups of eight animals each.
Ondansetron, dissolved in saline, at dosages of 2 and 4 mg/kg s.c.
or saline were injected 15 min before paracetamol (400 mg/kg i.p.) (dis-
solved in vehicle, which consisted of 12.5% of 1,2-propanediol in ster-
ile saline) or vehicle and the animals were subjected to the hot-plate test
or to paw pressure test 30 min later. This dose of paracetamol was sched-
uled as being effective in our experimental conditions on the basis of
dose-response experiments in the test performed in our laboratory under
identical experimental conditions [6]; the used doses of ondansetron
have been selected in the range of those proved to be effective in pre-
venting the antinociceptive activity of acetylsalicylic acid [18].
CP 93129 or saline was injected at the doses of 0.5, 1 and 2 mg/kg
s.c. 15 min before paracetamol or vehicle; the rats were subject to the
above described behavioural tests following the same experimental
schedule.
Control experiments showed no significant difference in response
to saline and 12.5% of 1,2-propanediol in the concentration used, so the
data have been pooled. Control rats, paracetamol-, ondansetron- 
(4 mg/kg) and ondansetron plus paracetamol-treated rats were anaes-
thetized and decapitated immediately after the hot-plate test; their
brains were removed and areas dissected and stored at –80°C until
required for assay.
Hot-plate test
The hot-plate consisted of an electrically-heated surface (Socrel DS-35,
Ugo Basile, Comerio, VA, Italy) kept at a constant temperature of 54 ±
0.4°C. The latencies for paw licking or jumping were recorded for each
animal. The analgesic efficacy of the drug was evaluated as a percent-
age of the maximum possible effect (% MPE), according to the formu-
la (TL–BL)/(45–BL) ¥ 100, where TL = Test Latency, BL = Baseline
Latency, 45 = cut-off time, in seconds.
Paw pressure test
The rats were submitted to the paw pressure test previously described by
Randall and Selitto [19]. Nociceptive threshold, expressed in grams,
was measured with an algesimeter (Apelex tipe; tip diameter of probe 
1 mm) from Ugo Basile (Comerio, VA, Italy), applying increasing pres-
sure (15 g per sec) in the left paw of rats until the paw withdrawal was
obtained after a sort of struggle. Results were expressed as a percentage
of the maximum possible effect (% MPE), according to the formula
(TL–BL)/(750–BL) ¥ 100, where TL = Test Latency (in grams), BL =
Baseline Latency (in grams), cut-off value: 750 g.
Binding assay
The characteristics of 5-HT3 binding sites were evaluated according to
Kilpatrick and co-workers [20] with minor modifications, using six
concentrations of [3H]GR65630 (0.1–4 nM; specific activity: 
80 Ci/mmol). Frontal cortex, temporal-parietal cortex and midbrain
were homogenized in 10 ml of HEPES buffer (50 mM, pH 7.4, 4°C)
(Ultra Turrax, 15 sec) and centrifuged for 10 min at 48000 ¥ g in a
Beckman centrifuge at 4°C. The supernatant was discharged, the pellet
was resuspended and, after homogenisation in the same buffer, cen-
trifuged again.
Aliquots of the membrane suspension were used for saturation stud-
ies. Non specific binding was determined by metoclopramide (50 mM).
The mixture of membranes, paracetamol and HEPES or metoclo-
pramide was incubated at 37°C for 30 min and the assay was stopped by
filtration under reduced pressure through GF/B filters, which had been
pre-soaked in 0.1% polyethyleneimine and rinsed with 5 ¥ 3 ml of
HEPES at room temperature. Filters were transferred into plastic vials
containing 6 ml of Packard Optiluor. The vials were stored overnight at
room temperature before being counted.
Competition binding experiments used 10 concentrations between
0.1 nM and 100 mM unlabelled paracetamol to displace binding of 1 nM
[3H]GR65630. Binding assay was then performed according to the
above method.
Drugs
Paracetamol, metoclopramide and HEPES were purchased from Sigma-
Aldrich Srl (Milan, Italy); ondansetron was kindly provided by Glaxo
Ltd (Verona, Italy); CP 93129 was purchased by Tocris Cookson Ltd.
(Bristol, Great Britain); [3H]GR65630 (specific activity, 80 Ci/mmol)
was from Du Pont NEN (Milan, Italy).
Data analysis
The results of binding experiments were analysed according to the
method of Rosenthal. The equilibrium dissociation constant (kD) and the
maximum number of binding sites (Bmax,) were evaluated individually
for each sample with six concentrations of labelled drug using the
regression analysis; binding parameters were calculated from the plot
[21].
The data obtained from the hot-plate and paw pression tests and
from binding experiments were expressed as means ± SEM and corre-
lated by using one-way analysis of variance (ANOVA) followed, when
F-value was significant, by the Student-Newman-Keuls test in case that
the effects of ondansetron or CP 93129 and paracetamol were evaluat-
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ed separately. A two-way analysis of variance was used to analyse the
effect of ondansetron or CP 93129 pre-treatment, paracetamol treatment
and their interaction, followed by 2 ¥ 2 factorial analysis by means of
orthogonal comparisons. The level of significance was set at 0.05.
Results
Behavioural experiments
Paracetamol (400 mg/kg) significantly increased the %MPE
values in the hot-plate test, as expected. At the dose of 
4 mg/kg, ondansetron alone slightly but not significantly
increased %MPE values (Fig. 1), while, at the doses of 2 and
4 mg/kg, it only slightly reduced the antinociceptive effect of
paracetamol in a non-significant manner. ANOVA showed
significance (p = 0.001) and the Student-Newman-Keuls test
demonstrated that paracetamol- and ondansetron (2 and 
4 mg/kg) plus paracetamol-values were significantly differ-
ent from control values but not from each other. The interac-
tion test showed no significance [F(l–42) = 2.06; p > 0.05
and F(l–42) = 2.43; p > 0.05 for ondansetron 2 and 4 mg/kg,
respectively]. The effect of ondansetron was not dose-depen-
dent as the increase in %MPE values provoked by paraceta-
mol was reduced in a similar manner by the two doses
(–17.1% and –18.5%, respectively).
Paracetamol (400 mg/kg) showed significant antinoci-
ceptive effect in the paw pressure test as well (Fig. 2).
Ondansetron (at any dose used) did not affect the paw pres-
sure test since the control values were no different from 
those of the treated rats and it did not antagonise the anal-
gesic effect of paracetamol. ANOVA showed significance 
(p = 0.002) and the Student-Newman-Keuls test indicated
that ondansetron (at any dose) plus paracetamol-values were
no different from paracetamol ones; interaction test showed
no significance [F(l–42) = 0.04; p 0.05 and F(l–42) = 0.01;
p > 0.05 for ondansetron 2 and 4 mg/kg, respectively].
CP 93129, at the dose of 2 mg/kg, significantly prevent-
ed the analgesic effect of paracetamol in the hot-plate test
(Fig. 3). ANOVA showed significance (p = 0.001): the Stu-
dent-Newman-Keuls test indicated that CP 93129 (2 mg/kg)
plus paracetamol-values were different from paracetamol
ones; [interaction test: F(1–56) = 4.24; p < 0.05] while the
lower doses were ineffective in inducing a antagonistic effect
[F(l–56) = 0.86; p > 0.05 and F(l–56) = 0.04; p > 0.05 for
0.5 and 1 mg/kg, respectively].
CP 93129 (2 mg/kg) significantly antagonised the
antinociceptive effect of paracetamol also in the paw pres-
sure test (Fig. 4) [ANOVA: p = 0.001; interaction test:
F(l–56) = 8.7; p < 0.01], while the lower doses were com-
pletely inactive since the values of CP 93129 (0.5 and 
1 mg/kg) plus paracetamol were significantly higher than
control values and similar to those of paracetamol alone
[F(l–56) = 0.08; p > 0.05 and F(l–56) = 0.01; p > 0.05 for
0.5 and 1 mg/kg, respectively].
Receptor binding studies
In the three areas considered (frontal cortex, temporal-pari-
etal cortex and midbrain) paracetamol was not able to modi-
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Fig. 1. Influence of ondansetron (ONDA, 2 or 4 mg/kg s.c.) pre-treat-
ment on the antinociceptive action of paracetamol (PARA, 400 mg/kg
i.p.) in the hot-plate test. Paracetamol was administered 15 min after
ONDA and the rats were tested 30 min later. Each histogram represents
the percentage of the maximum possible effect (%MPE); values were
expressed as means ± SEM for eight rats for each group. SAL = saline
VEH = vehicle consisting in 12,5% of 1,2 propanediol in sterile saline.
*p < 0.05 vs control values (ANOVA followed by Student-Newman-
Keuls test).
Fig. 2. Influence of ondansetron (ONDA, 2 or 4 mg/kg s.c.) pre-treat-
ment on the antinociceptive action of paracetamol (PARA, 400 mg/kg
i.p.) in the paw pressure test. PARA was administered 15 min after
ONDA and the rats were tested 30 min later. Each histogram represents
the percentage of the maximum possible effect (%MPE); values were
expressed as means ± SEM for eight rats for each group. SAL = saline
VEH = vehicle consisting in 12,5% of 1,2 propanediol in sterile saline.
*p < 0.05 vs control values (ANOVA followed by Student-Newman-
Keuls test).
fy either the maximum number (Bmax) or the affinity constant
(kD) of 5-HT3 receptors. Treatment with ondansetron 
(4 mg/kg i.p.) significantly increased the number of 5-HT3
receptors in the three areas studied while ondansetron +
paracetamol values were no different from those obtained
with ondansetron alone (ANOVA: p = 0.001 for the three
areas investigated). The affinity constant remained un-
affected by any of the treatments (ANOVA: p = 0.997, 
p = 0.131 and p = 0.991 for frontal cortex, temporal-parietal
cortex and midbrain, respectively) (Table 1).
Factorial analysis showed no interaction between
ondansetron and paracetamol treatment in the frontal cortex
[F(l–28) = 1.31, p > 0.05], the temporal-parietal cortex
[F(l–28) = 3.47, p > 0.05] or the midbrain [F(l–28) = 0.12,
p > 0.05].
Finally, paracetamol did not bind to 5-HT3 binding sites.
Competition experiments demonstrated that, at doses rang-
ing between 10–9 and 10–4 M, paracetamol was not able to dis-
place, in vitro, the binding of 1 nM [3H]GR65630 in the three
areas studied.
Discussion
The present results confirm that paracetamol (400 mg/kg) is
able to induce an antinociceptive activity in the two algesi-
metric tests, the hot-plate test and the paw pressure test, in the
rat, significantly increasing the %MPE values. The analgesic
effect of paracetamol has been obtained after systemic
administration in animals using a variety of behavioural tests
chiefly in models devoid of inflammation, and similar results
have been obtained in humans [22]. A spinal site of action has
been suggested by many authors for the analgesic effect of
paracetamol [4, 23, 24]. Moreover, the involvement of the
central serotonergic system in the analgesia induced by non-
opioid analgesics has been demonstrated [3], but the detailed
mechanism by which serotonin acts, together with the exact
nature of the receptor subtypes involved, has not yet been elu-
cidated [25–27].
It has been suggested that serotonin modulates the
response to noxious stimuli either at spinal or supraspinal
levels: serotonin and serotonin agonists, injected both
peripherally and in discrete brain areas, raise the nociceptive
threshold, while serotonin receptor blockers attenuate anal-
gesia at spinal and supraspinal levels [28, 29].
Some authors claim the involvement of spinal 5-HT3
receptors in the antinociceptive effect of paracetamol [5, 9],
suggesting an indirect action, since paracetamol does not
bind to 5-HT3 receptors. Our results confirm that paraceta-
mol does not bind to 5-HT3 receptors even at supraspinal lev-
el. On the other hand, our data demonstrate that, at supra-
spinal level, these receptors are not involved in the antinoci-
ceptive effect of paracetamol, in our conditions, as evaluated
by means of the hot-plate and the paw pressure tests.
Ondansetron alone increases the number of 5-HT3 receptors;
this effect was not modified by the treatment with paraceta-
350 M. Sandrini et al. Inflamm. res.
Fig. 3. Influence of CP 93129 (CP, 0,5, 1 or 2 mg/kg s.c.) pre-treatment
on the antinociceptive action of paracetamol (PARA, 400 mg/kg i.p.) in
the hot-plate test. PARA was administered 15 min after CP 93129 and
the rats were tested 30 min later. Each histogram represents the per-
centage of the maximum possible effect (%MPE); values were
expressed as means ± SEM for eight rats for each group. SAL = saline
VEH = vehicle consisting in 12,5% of 1,2 propanediol in sterile saline.
*p < 0.05 vs control values; *p < 0.05 vs SAL + PARA values (ANO-
VA followed by Student-Newman-Keuls test).
Fig. 4. Influence of CP 93129 (CP, 0,5, 1 or 2 mg/kg s.c.) pre-treatment
on the antinociceptive action of paracetamol (PARA, 400 mg/kg i.p.) in
the paw pressure test. PARA was administered 15 min after CP 93129
and the rats were tested 30 min later. Each histogram represents the per-
centage of the maximum possible effect (%MPE); values were
expressed as means ± SEM for eight rats for each group. SAL = saline
VEH = vehicle consisting in 12,5% of 1,2 propanediol in sterile saline.
*p < 0.05 vs control values; *p < 0.05 vs SAL + PARA values (ANO-
VA followed by Student-Newman-Keuls test).
Table 1. Influence of ondansetron on the effect of paracetamol on [3H]GR65630 binding evaluations in the frontal and temporal-parietal cortex and
midbrain of the rat.
Treatment Frontal  cortex Temporal-parietal cortex Midbrain
Bmax kD Bmax kD Bmax kD
(fmol/mg prot) (nM) (fmol/mg prot) (nM) (fmol/mg prot) (nM)
SAL + VEH 175.33 ± 20.22 1.68 ± 0.31 198.58 ± 14.41 1.61 ± 0.13 164.85 ± 11.30 1.26 ± 0.07
SAL + PARA 151.95 ± 8.42 1.62 ± 0.10 152.51 ± 9.54 1.41 ± 0.18 135.18 ± 9.68 1.28 ± 0.17
ONDA + VEH 291.27 ± 16.78* 1.87 ± 0.44 271.60 ± 21.42* 1.97 ± 0.24 265.02 ± 17.88* 1.33 ± 0.21
ONDA + PARA 308.71 ± 22.34* 1.73 ± 0.23 295.7 ± 23.23* 1.51 ± 0.12 244.20 ± 12.28* 1.31 ± 0.19
Ondansetron (ONDA, 4 mg/kg, s.c.) or saline (SAL) were administered 15 min before paracetamol (PARA, 400 mg/kg, i.p.) or vehicle (VEH, con-
sisting in 12,5% of 1,2 propanediol in sterile saline) treatment. Rats were killed immediately after the hot-plate test (30 min after the last treatment)
and the brain areas were weighed and frozen at –80°C until assayed. Each value represents the mean ± SEM of 8 separate experiments and were
derived from Rosenthal plot. Bmax = maximum binding capacity: kD = equilibrium dissociation constant. *p < 0.05 vs control values (ANOVA fol-
lowed by Student-Newman-Keuls test).
mol, thus indicating that these two drugs do not display an
interactive effect. In particular, paracetamol fails to affect the
characteristics of 5-HT3 receptors even in coadministration,
as shown by the results of the interaction tests. This interest-
ing effect of ondansetron on the number of 5-HT3 receptors
may be partially explained by the role of these receptors in
the modulation of 5-HT release and by the involvement also
of other neurotransmitters [30]. On the other hand, it is well
known that the number of serotonin receptors is down- or up-
regulated by the serotonin levels and by the interaction with
5-HT agonists and antagonists, respectively, after acute expo-
sure and even in a relatively short period of time [31]. Indeed,
the block of 5-HT3 receptors by ondansetron may induce an
up-regulation of these receptor subtype which allows para-
cetamol to exert its antinociceptive effect.
These results contribute to the body of conflicting evi-
dence concerning the role of the 5-HT3 receptor subtypes in
the nociceptive activity of paracetamol [32]. The antinoci-
ceptive effect of paracetamol may be mediated by different
serotonin receptor subtypes at spinal and supraspinal levels.
This is suggested a) by the results obtained by some authors
indicating that the activity of paracetamol is prevented by 
5-HT3 receptor antagonist tropisetron, when intrathecally
(i. t.) injected [5] and b) by findings obtained in our laborato-
ry showing that the antinociceptive effect of paracetamol, in
the hot-plate test, is coupled to an increase in serotonin lev-
els and a decrease in the number of 5-HT2 receptors in the
cerebral cortex and in the pons [6]. Thus, in some brain areas,
the effect of paracetamol seems to be indirectly mediated
through an increase in the serotonin levels regulated by 
5-HT2 receptors. As already mentioned, paracetamol does
not act directly on serotonin receptors, as competition bind-
ing studies have demonstrated that it is not able to bind to 
5-HT1A, 5-HT2 and 5-HT3 receptors [33].
A possible explanation of the lack of antagonistic effect of
ondansetron on the behavioural profile may be afforded by
the heterogeneity observed between 5-HT3 receptor antago-
nists, as suggested by Bardin and co-workers [34–35]: they
show that the antagonism exerted by tropisetron and
granisetron against the i.t. 5-HT antinociceptive effect differs
in potency. Moreover, Courade and co-workers [27] demon-
strate that tropisetron, but not granisetron inhibits the effect of
acetaminophen in a mechanical pain test. On the other hand,
in the present work we report that ondansetron per se does not
induce any intrinsic effect in the two pain tests used, thus
behaving like tropisetron in a mechanical pain test [35].
Indeed, tropisetron has been shown to be not very selective for
5-HT3 receptors, as it binds also to other types of receptors
(e.g. GABAA). On the contrary, ondansetron and granisetron
have little or no affinity for 5-HT1A and 5-HT2 receptors, a1
and b1 adrenoceptors, muscarinic, nicotinic, dopaminergic
and H1 or GABAA receptors in rat cerebral cortex and vagus
nerve [36]. Therefore, the antagonistic effect on the analgesic
activity of paracetamol induced by the less selective 5-HT3
receptor antagonist tropisetron may be explained by its inter-
action with other types of receptor, while the more selective
antagonists fail to produce any specific effect. The binding
results obtained in the cortical areas and in the midbrain indi-
cate that ondansetron produces the same effects in different
areas involved in the serotonin-mediated pathways of the pain
modulatory system. In fact, it has been suggested that the cor-
tical areas are the end-point of the nociceptive system where
the noxious information is perceived and processed [37, 38],
while, in the midbrain, serotonin neurons, which project to the
spinal cord and other brain regions (chiefly the limbic and
cortical areas), are located.
It must also be borne in mind that these results have been
obtained using different behavioural tests (mechanical and
chemical pain) and routes of administration of drugs. The
importance of the type of pain test employed has been under-
lined [39, 40]; in the hot-plate test, the antinociceptive effect is
largely mediated by supraspinal mechanisms [41] and even the
paw pressure test can involve supraspinal structures [42]. The
lack of the antagonistic effect of ondansetron on the antinoci-
ception exerted by paracetamol in a thermal pain model is con-
firmed by using a mechanical pain model, the paw pressure
test, thus suggesting that the negative results obtained by
ondansetron treatment did not depend on the hot-plate test.
The diversity of effects exerted by paracetamol on noci-
ception at spinal and supraspinal levels, reported in the liter-
ature, may be due to a different density of serotonin receptors
subtypes [40]. Our results, however, are consistent with those
obtained, at spinal level, by Courade and co-workers [27]
using granisetron as 5-HT3 antagonist, thus indicating that,
also at supraspinal level, 5-HT3 receptors do not seem to be
involved in paracetamol-induced antinociception, as evaluat-
ed by means of two different pain models.
Moreover, we demonstrate that the 5-HT1B receptor agonist
CP 93129 can antagonise the effect of paracetamol in the two
pain tests used. This result is in keeping with that of Roca-
Vinardell and co-workers who showed an antagonist effect of
CP93129 on the antinociceptive activity of paracetamol in the
hot-plate test in mice [43]. CP 93129 is a specific 5-HT1B
receptor agonist, with 150 fold higher activity for 5-HT1B ver-
sus other 5-HT1, and 5-HT2 binding sites [44]. It is also
claimed to lack substantial affinity for dopamine, noradrena-
line or opioid receptors [45]. The 5-HT1B receptors present in
the CNS of rodents seem to be autoreceptors associated with a
decrease in transmitter release [46]; when stimulated, these
receptors exert a negative feedback control of serotonin [17].
We suggest that this decrease in 5-HT levels exerted by CP
93129 may counteract the increase of serotonin levels induced
by paracetamol preventing its antinociceptive effect.
These data add further evidence that serotonin is involved
in the central effect of paracetamol via a complex net of
receptor subtypes.
In conclusion, we suggest that the purported increase in
5-HT levels induced by paracetamol at a central level medi-
ates an activation of 5-HT receptor subtypes, depending on
the discrete brain areas investigated and on the region of the
5-HT inhibitory system taken into account. Finally, the role
of 5-HT1B, 5-HT2 and 5-HT3 receptors in the 5-HT-induced
nociception still remains to be fully clarified as does the
nature of the molecular mechanisms involved in the relation-
ship involving paracetamol, serotonin and nociception.
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